These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 30696721)

  • 1. Clinicopathological and Preclinical Findings of NUT Carcinoma: A Multicenter Study.
    Jung M; Kim S; Lee JK; Yoon SO; Park HS; Hong SW; Park WS; Kim JE; Kim J; Keam B; Kim HJ; Kang HJ; Kim DW; Jung KC; Kim YT; Heo DS; Kim TM; Jeon YK
    Oncologist; 2019 Aug; 24(8):e740-e748. PubMed ID: 30696721
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The dual HDAC-PI3K inhibitor CUDC-907 displays single-agent activity and synergizes with PARP inhibitor olaparib in small cell lung cancer.
    Ma L; Bian X; Lin W
    J Exp Clin Cancer Res; 2020 Oct; 39(1):219. PubMed ID: 33069237
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual HDAC and PI3K Inhibitor CUDC-907 Downregulates MYC and Suppresses Growth of MYC-dependent Cancers.
    Sun K; Atoyan R; Borek MA; Dellarocca S; Samson ME; Ma AW; Xu GX; Patterson T; Tuck DP; Viner JL; Fattaey A; Wang J
    Mol Cancer Ther; 2017 Feb; 16(2):285-299. PubMed ID: 27980108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemical Screen Identifies Diverse and Novel Histone Deacetylase Inhibitors as Repressors of NUT Function: Implications for NUT Carcinoma Pathogenesis and Treatment.
    Shiota H; Alekseyenko AA; Wang ZA; Filic I; Knox TM; Luong NM; Huang Y; Scott DA; Jones KL; Gokhale PC; Lemieux ME; Cole PA; Kuroda MI; French CA
    Mol Cancer Res; 2021 Nov; 19(11):1818-1830. PubMed ID: 34285087
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CUDC-907 displays potent antitumor activity against human pancreatic adenocarcinoma in vitro and in vivo through inhibition of HDAC6 to downregulate c-Myc expression.
    Fu XH; Zhang X; Yang H; Xu XW; Hu ZL; Yan J; Zheng XL; Wei RR; Zhang ZQ; Tang SR; Geng MY; Huang X
    Acta Pharmacol Sin; 2019 May; 40(5):677-688. PubMed ID: 30224636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual targeting of bromodomain-containing 4 by AZD5153 and BCL2 by AZD4320 against B-cell lymphomas concomitantly overexpressing c-MYC and BCL2.
    Takimoto-Shimomura T; Tsukamoto T; Maegawa S; Fujibayashi Y; Matsumura-Kimoto Y; Mizuno Y; Chinen Y; Shimura Y; Mizutani S; Horiike S; Taniwaki M; Kobayashi T; Kuroda J
    Invest New Drugs; 2019 Apr; 37(2):210-222. PubMed ID: 29931583
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic targeting of p300/CBP HAT domain for the treatment of NUT midline carcinoma.
    Zhang X; Zegar T; Lucas A; Morrison-Smith C; Knox T; French CA; Knapp S; Müller S; Siveke JT
    Oncogene; 2020 Jun; 39(24):4770-4779. PubMed ID: 32366905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Bromodomain Inhibitor JQ1 and the Histone Deacetylase Inhibitor Panobinostat Synergistically Reduce N-Myc Expression and Induce Anticancer Effects.
    Shahbazi J; Liu PY; Atmadibrata B; Bradner JE; Marshall GM; Lock RB; Liu T
    Clin Cancer Res; 2016 May; 22(10):2534-44. PubMed ID: 26733615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CUDC-907 exhibits potent antitumor effects against ovarian cancer through multiple in vivo and in vitro mechanisms.
    Wang Y; Wen J; Sun X; Sun Y; Liu Y; Cheng X; Wu W; Liu Q; Ren F
    Cancer Chemother Pharmacol; 2024 Apr; 93(4):295-306. PubMed ID: 37938423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NUT Carcinoma: Clinicopathologic features, pathogenesis, and treatment.
    French CA
    Pathol Int; 2018 Nov; 68(11):583-595. PubMed ID: 30362654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intensive treatment and survival outcomes in NUT midline carcinoma of the head and neck.
    Chau NG; Hurwitz S; Mitchell CM; Aserlind A; Grunfeld N; Kaplan L; Hsi P; Bauer DE; Lathan CS; Rodriguez-Galindo C; Tishler RB; Haddad RI; Sallan SE; Bradner JE; French CA
    Cancer; 2016 Dec; 122(23):3632-3640. PubMed ID: 27509377
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Response of Carcinomas Harboring the BRD4-NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628.
    Stathis A; Zucca E; Bekradda M; Gomez-Roca C; Delord JP; de La Motte Rouge T; Uro-Coste E; de Braud F; Pelosi G; French CA
    Cancer Discov; 2016 May; 6(5):492-500. PubMed ID: 26976114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies.
    Rhyasen GW; Hattersley MM; Yao Y; Dulak A; Wang W; Petteruti P; Dale IL; Boiko S; Cheung T; Zhang J; Wen S; Castriotta L; Lawson D; Collins M; Bao L; Ahdesmaki MJ; Walker G; O'Connor G; Yeh TC; Rabow AA; Dry JR; Reimer C; Lyne P; Mills GB; Fawell SE; Waring MJ; Zinda M; Clark E; Chen H
    Mol Cancer Ther; 2016 Nov; 15(11):2563-2574. PubMed ID: 27573426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dual inhibition of HDAC and tyrosine kinase signaling pathways with CUDC-907 attenuates TGFβ1 induced lung and tumor fibrosis.
    Zhang W; Zhang Y; Tu T; Schmull S; Han Y; Wang W; Li H
    Cell Death Dis; 2020 Sep; 11(9):765. PubMed ID: 32943605
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CUDC-907, a novel dual PI3K and HDAC inhibitor, in prostate cancer: Antitumour activity and molecular mechanism of action.
    Hu C; Xia H; Bai S; Zhao J; Edwards H; Li X; Yang Y; Lyu J; Wang G; Zhan Y; Dong Y; Ge Y
    J Cell Mol Med; 2020 Jul; 24(13):7239-7253. PubMed ID: 32459381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel dual epigenetic approach targeting BET proteins and HDACs in Group 3 (MYC-driven) Medulloblastoma.
    Kling MJ; Kesherwani V; Mishra NK; Alexander G; McIntyre EM; Ray S; Challagundla KB; Joshi SS; Coulter DW; Chaturvedi NK
    J Exp Clin Cancer Res; 2022 Nov; 41(1):321. PubMed ID: 36357906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The BRD4-NUT Fusion Alone Drives Malignant Transformation of NUT Carcinoma.
    Durall RT; Huang J; Wojenski L; Huang Y; Gokhale PC; Leeper BA; Nash JO; Ballester PL; Davidson S; Shlien A; Sotirakis E; Bertaux F; Dubus V; Luo J; Wu CJ; Keskin DB; Eagen KP; Shapiro GI; French CA
    Cancer Res; 2023 Dec; 83(23):3846-3860. PubMed ID: 37819236
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual inhibition of histone deacetylases and phosphoinositide 3-kinase enhances therapeutic activity against B cell lymphoma.
    Mondello P; Derenzini E; Asgari Z; Philip J; Brea EJ; Seshan V; Hendrickson RC; de Stanchina E; Scheinberg DA; Younes A
    Oncotarget; 2017 Feb; 8(8):14017-14028. PubMed ID: 28147336
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NUT carcinoma in children and adults: A multicenter retrospective study.
    Lemelle L; Pierron G; Fréneaux P; Huybrechts S; Spiegel A; Plantaz D; Julieron M; Dumoucel S; Italiano A; Millot F; Le Tourneau C; Leverger G; Chastagner P; Carton M; Orbach D
    Pediatr Blood Cancer; 2017 Dec; 64(12):. PubMed ID: 28643357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New developments in the molecular pathogenesis of head and neck tumors: a review of tumor-specific fusion oncogenes in mucoepidermoid carcinoma, adenoid cystic carcinoma, and NUT midline carcinoma.
    Bhaijee F; Pepper DJ; Pitman KT; Bell D
    Ann Diagn Pathol; 2011 Feb; 15(1):69-77. PubMed ID: 21238915
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.